Outstanding Recoveries
- Home
- Outstanding Recoveries
Verdicts & Settlements
Since Milberg’s founding in 1965, the firm has recovered more than $50 billion for our clients while prompting meaningful changes in corporate governance.
-
See More$15.25 Million Settlement – Plantation Building of Wilmington, Inc. v. Brunswick County
Plantation Building of Wilmington, Inc. v. Brunswick County, Brunswick Co. File No. 19-CVS-647 (NC)$15.25 million class settlement on behalf of developers and home builders for illegally charged water and sewer capital recovery fees. -
See More$1 Billion Settlement – W.R. Grace & Co
In re W.R. Grace & Co., Nos. 02-2210 and 02-2211 (D. Del.)In this case, Milberg acted as Lead Counsel for the asbestos personal injury and property damage committees in two separate fraudulent conveyance actions within the W.R. Grace bankruptcy. Two settlements were achieved, consisting of cash and stock valued at approximately $1 billion. -
See More$1.25 Billion Settlement – Black Farmers Discrimination Litigation
In re Black Farmers Discrimination Litigation, Case Number 08-mc-0511 (U.S. District Court for the District of Columbia)Milberg attorneys were appointed Lead Counsel and secured a $1.25 billion settlement fund for black farmers who alleged the U.S. Department of Agriculture discriminated against them by denying farm loans. -
See More$106 Million Settlement – Daedalus, LLC v. City of Charlotte
Daedalus, LLC v. City of Charlotte, Mecklenburg Co. File No. 18-CVS-21073 (NC)$106 million class settlement on behalf of developers and home builders for illegally charged water and sewer capacity fees. -
See More$3.4 Billion Settlement – Avandia Marketing, Sales Practices, and Products Liability Litigation
In re Avandia Marketing, Sales Practices, and Products Liability Litigation, MDL 1871 (U.S. District Court for the Eastern District of Pennsylvania)Milberg attorneys were appointed to the Plaintiffs Steering Committee and served on the Discovery and Media Sub-Committees on behalf of thousands of patients who took the Type 2 diabetes drug Avandia, alleging the manufacturer failed to disclose the known and increased risk of heart attack and cardiac death. GlaxoSmithKline set aside $3.4 billion in 2011 to settle lawsuits.